Engelman JA - Search Results

1

The present and future of PI3K inhibitors for cancer therapy.

Castel P, Toska E, Engelman JA, Scaltriti M. Castel P, et al. Among authors: engelman ja. Nat Cancer. 2021 Jun;2(6):587-597. doi: 10.1038/s43018-021-00218-4. Epub 2021 Jun 17. Nat Cancer. 2021. PMID: 35118422 Free PMC article.

2

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.

Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS. Isakoff SJ, et al. Among authors: engelman ja. Cancer Res. 2005 Dec 1;65(23):10992-1000. doi: 10.1158/0008-5472.CAN-05-2612. Cancer Res. 2005. PMID: 16322248

3

The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.

Engelman JA. Engelman JA. Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4637-40. doi: 10.1158/1078-0432.CCR-07-0653. Clin Cancer Res. 2007. PMID: 17671156 Review.

4

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Engelman JA, Jänne PA. Engelman JA, et al. Clin Cancer Res. 2008 May 15;14(10):2895-9. doi: 10.1158/1078-0432.CCR-07-2248. Clin Cancer Res. 2008. PMID: 18483355 Review.

5

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK. Engelman JA, et al. Nat Med. 2008 Dec;14(12):1351-6. doi: 10.1038/nm.1890. Epub 2008 Nov 30. Nat Med. 2008. PMID: 19029981 Free PMC article.

6

Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Engelman JA. Engelman JA. Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664. Nat Rev Cancer. 2009. PMID: 19629070 Review.

7

Targeting the PI3K signaling pathway in cancer.

Wong KK, Engelman JA, Cantley LC. Wong KK, et al. Among authors: engelman ja. Curr Opin Genet Dev. 2010 Feb;20(1):87-90. doi: 10.1016/j.gde.2009.11.002. Epub 2009 Dec 16. Curr Opin Genet Dev. 2010. PMID: 20006486 Free PMC article. Review.

8

The PI3K pathway as drug target in human cancer.

Courtney KD, Corcoran RB, Engelman JA. Courtney KD, et al. Among authors: engelman ja. J Clin Oncol. 2010 Feb 20;28(6):1075-83. doi: 10.1200/JCO.2009.25.3641. Epub 2010 Jan 19. J Clin Oncol. 2010. PMID: 20085938 Free PMC article. Review.

9

Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer.

Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, Engelman JA, Du Y, Andreeff M, Hortobagyi GN, Hung MC. Yang JY, et al. Among authors: engelman ja. Cancer Res. 2010 Jun 1;70(11):4709-18. doi: 10.1158/0008-5472.CAN-09-4524. Epub 2010 May 18. Cancer Res. 2010. PMID: 20484037 Free PMC article.

10

PIKing the right patient.

Turke AB, Engelman JA. Turke AB, et al. Among authors: engelman ja. Clin Cancer Res. 2010 Jul 15;16(14):3523-5. doi: 10.1158/1078-0432.CCR-10-1201. Epub 2010 Jun 10. Clin Cancer Res. 2010. PMID: 20538763

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

229 results

Search Page

Filters